Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Standard Biotools Inc

Company price
0.64 USD 0.03 ( 4.29%)
Last update at 2026-11-20T21:00:00Z
VOLUME
2773172
Market Cap
274.77M

Momentum Score

…

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.57
Low
0.64
High
52 Week Price Range
0.63
Low
1.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Standard Biotools Inc develops instruments, reagents and software for single-cell genomics and proteomics used by research and clinical labs. Long-term growth may be driven by expanding demand for single-cell and spatial biology, recurring consumables and adoption of multi-omics workflows, and the company appears positioned to benefit from researchers' shift toward higher-resolution cell analysis.

Key risks include intense competition from larger genomics vendors, rapid technological change that could erode product advantages, and variability in capital-equipment purchases and consumable demand that could reduce revenue visibility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.61
Dividend Yield
-
Revenue TTM
84.60M
Revenue Per Share
0.22
Gross Profit TTM
42.71M
Debt / Equity
0.07
ROE
-11.18%
Net Debt
-87.39M
ROCE
-21.04%
Diluted EPS TTM
-0.13

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -96.70M -138.31M -74.20M -192.93M -63.66M
Net income -74.90M -138.88M -74.66M -190.10M -59.24M
Selling general administrative 109.86M 156.61M 98.88M 114.76M 98.89M
Gross profit 42.54M 84.26M 50.45M 37.05M 77.27M
Reconciled depreciation 10.98M 16.86M 14.89M 15.03M 15.57M
Ebit -96.68M -135.00M -69.64M -116.20M -67.46M
Ebitda -89.69M -118.14M -54.46M -113.49M -67.46M
Depreciation and amortization 6.98M 16.86M 15.18M 2.72M 23.20M
Non operating income net other - - - 1.25M -
Operating income -93.31M -175.24M -76.60M -116.20M -67.46M
Other operating expenses 178.64M 349.67M 182.94M 214.15M 198.04M
Interest expense 0.03M 3.32M 4.57M 4.33M 3.82M
Tax provision -37.88M 0.57M 0.68M -2.83M -4.42M
Interest income 9.18M 20.20M 5.57M 64.41M 3.82M
Net interest income 9.15M 16.88M -4.66M -4.33M -3.82M
Extraordinary items -16.07M -47.95M - - -
Income tax expense -37.88M 0.57M 0.45M -2.83M -4.42M
Total revenue 85.33M 174.43M 106.34M 97.95M 130.58M
Total operating expenses 135.85M 259.50M 127.05M 153.26M 144.72M
Cost of revenue 42.79M 90.17M 55.89M 60.90M 53.31M
Total other income expense net -3.40M 36.92M 2.40M -76.72M 3.80M
Net income from continuing ops -58.83M -138.88M -75.72M -190.10M -59.24M
Net income applicable to common shares -74.90M -184.90M -74.66M -190.10M -59.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 567.75M 612.34M 323.07M 390.31M 275.21M
Intangible assets - 28.95M 1.41M 12.60M 27.93M
Other current assets 233.28M 8.66M 3.13M 4.28M 4.47M
Total liab 143.46M 140.62M 159.87M 471.78M -54.10M
Total stockholder equity 424.29M 471.72M 163.20M -81.47M 94.60M
Other current liab 58.46M 27.22M 20.57M 15.33M 13.59M
Common stock 0.40M 0.40M 0.08M -81.47M 0.08M
Capital stock 0.40M 0.40M 0.08M -81.47M 0.08M
Retained earnings -1260.55M -1185.65M -1000.75M -926.10M -736.00M
Other liab - - - 20.19M 29.29M
Good will - 111.30M 106.32M 106.25M 106.38M
Other assets - - - 3.11M 2.43M
Cash 118.21M 166.73M 51.70M 81.31M 28.45M
Cash and equivalents - - - 81.31M 28.45M
Total current liabilities 108.31M 65.89M 109.33M 43.44M -54.10M
Current deferred revenue 38.95M 18.59M 15.67M 14.44M 15.48M
Net debt -87.39M -133.73M 46.51M 21.35M 83.20M
Short term debt 5.49M 6.23M 63.85M 5.76M 9.89M
Short long term debt - - 59.53M 2.08M 6.84M
Short long term debt total 30.83M 33.00M 98.21M 102.66M 111.65M
Other stockholder equity 1685.93M 1655.75M 854.84M 616.74M 831.42M
Property plant equipment - - - 59.53M 65.15M
Total current assets 454.26M 375.88M 158.22M 208.81M 72.07M
Long term investments 25.70M 0.00M - - -
Net tangible assets - - - 110.94M -40.97M
Short term investments 69.36M 126.15M 63.19M 84.47M -
Net receivables 13.43M 33.61M 19.66M 17.28M 18.32M
Long term debt 0.30M 0.30M 3.98M 62.81M 64.21M
Inventory 19.98M 40.74M 20.53M 21.47M 20.82M
Accounts payable 5.41M 12.28M 9.24M 7.91M 10.60M
Accumulated other comprehensive income -1.49M 1.23M -2.22M -1.90M -0.91M
Common stock total equity - - - 0.08M -
Retained earnings total equity - - - -926.10M -
Non currrent assets other 3.15M 24.83M 1.48M 3.11M 3.69M
Non current assets total 113.49M 236.46M 164.85M 181.50M 203.15M
Capital lease obligations 30.53M 32.70M 34.70M 37.76M 40.60M
Long term debt total - - - 62.81M 64.21M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 40.71M 363.17M 73.60M -88.13M -11.95M
Change to liabilities - - - -8.75M -1.93M
Total cashflows from investing activities 24.77M 363.17M 20.24M -88.13M -11.95M
Net borrowings 0.00M -63.19M -2.08M 5.62M 16.34M
Total cash from financing activities 0.57M -102.62M -6.81M 230.76M 15.96M
Change to operating activities - - - -1.83M -19.95M
Net income -74.90M -138.88M -74.66M -190.10M -59.24M
Change in cash -48.17M 116.32M -29.82M 52.86M -40.07M
Begin period cash flow 168.82M 52.50M 82.32M 29.47M 69.54M
End period cash flow 120.65M 168.82M 52.50M 82.32M 29.47M
Total cash from operating activities -74.35M -143.45M -43.29M -89.37M -44.06M
Issuance of capital stock - 0.00M 0.00M 225.00M 0.00M
Depreciation 1.72M 16.86M 15.18M 15.03M 11.92M
Other cashflows from investing activities -5.00M 92.88M 23.07M -84.30M 1.32M
Change to inventory -11.52M -9.88M -4.91M -8.47M 20.82M
Change to account receivables -1.36M 8.97M -2.99M 1.06M 18.32M
Sale purchase of stock 1.05M -40.95M -5.41M -0.56M 1.49M
Other cashflows from financing activities -0.48M 1.52M 0.69M 13.16M 15.96M
Change to netincome - - - 30.67M 18.42M
Capital expenditures 8.30M 8.36M 2.83M 3.83M 13.26M
Change receivables - - - 1.06M -
Cash flows other operating - - - 70.37M -
Cash and cash equivalents changes - - - 53.26M -
Change in working capital -44.98M -12.08M 1.79M -15.48M 49.75M
Stock based compensation 29.61M 31.73M 13.12M 14.88M 4.92M
Other non cash items 14.20M -41.08M 1.28M 86.30M -55.74M
Free cash flow -82.65M -151.81M -46.12M -93.19M -57.33M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LAB
Standard Biotools Inc
0.03
4.29%
0.64 - - 3.25 0.50 0.27 -19.22
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Standard Biotools Inc

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

50 Milk Street, Boston, MA, United States, 02109

650 266 6000

385

Name Title Year Born
Mr. Vikram Jog Chief Financial Officer 1956
Dr. Michael Egholm Ph.D. Pres, CEO & Director 1963
Dr. Stephen R. Quake D.phil., Ph.D. Co-Founder & Chairman of Advisory Board 1970
Mr. Hanjoon Kim Chief Operating Officer 1971
Mr. Andrew Quong Ph.D. Chief Science Officer NA
Mr. Peter DeNardo Investor Relations NA
Mr. Rafael Aguirre-Sacasa Acting Gen. Counsel NA
Mark Spearman Sr. Director of Corp. Communications NA
Ms. Angela Peters Chief HR Officer NA
Dr. David A. King Ph.D. Sr. VP of Global R&D NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…